Drugs that contain Lenacapavir Sodium

1. List of Sunlenca drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9951043 GILEAD SCIENCES INC Therapeutic compounds
Feb, 2034

(10 years from now)

US10071985 GILEAD SCIENCES INC Therapeutic compounds
Aug, 2037

(14 years from now)

US11267799 GILEAD SCIENCES INC Solid forms of an HIV capsid inhibitor
Aug, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10654827 GILEAD SCIENCES INC Therapeutic compounds
Aug, 2037

(14 years from now)

Do you want to check out SUNLENCA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 22, 2027

NCE-1 date: 2026-12-22

Market Authorisation Date: 22 December, 2022

Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection


More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in